Ipsen shares drop after FDA approval of U.S. generic rival
Ipsen shares fell 6.6% to a seven-month low of 145.60 euros in morning European trade after the FDA approved a U.S. generic competitor to Ipsen’s flagship hormone drug earlier than expected.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.